8-K filed January 26, 2024, 6:59 PM ET ticker DARE CIK 0001401914

leadership confidence high sentiment neutral materiality 0.55

Dare Bioscience announces CFO retirement, CCO resignation, board downsizing

Dare Bioscience, Inc.

CFO Lisa Walters-Hoffert retired effective Jan. 26, 2024; will consult for 9 months at $31,667/month.
CCO John Fair resigns effective June 30, 2024; part-time from Apr. 1; no replacement planned.
MarDee Haring-Layton appointed Chief Accounting Officer; CEO Johnson will serve as principal financial officer.
Board to shrink from 8 to 6; directors Blanchard and Ononye-Onyia to resign before 2024 annual meeting.
Non-employee director cash compensation reduced to 25th percentile of peer group.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Fair

Chief Commercial Officer

DARE · Dare Bioscience, Inc.

Effective: 2024-06-30
Filed: January 26, 2024, 6:59 PM ET

On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATO TM —bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024.

Appointed

MarDee Haring-Layton

Chief Accounting Officer

DARE · Dare Bioscience, Inc.

Effective: 2024-01-26
Filed: January 26, 2024, 6:59 PM ET

Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer.

Departed

Lisa Walters-Hoffert

Chief Financial Officer

DARE · Dare Bioscience, Inc.

Effective: 2024-01-26
Filed: January 26, 2024, 6:59 PM ET

On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.

Role change

Sabrina Martucci Johnson

Chief Executive Officer and President

DARE · Dare Bioscience, Inc.

Effective: 2024-01-26
Filed: January 26, 2024, 6:59 PM ET

Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Fair resigned as Chief Commercial Officer at Dare Bioscience, Inc..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATO TM —bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

MarDee Haring-Layton was appointed as Chief Accounting Officer at Dare Bioscience, Inc..

Action: appointed
Role: Chief Accounting Officer

Exact text from the filing

Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Walters-Hoffert retired as Chief Financial Officer at Dare Bioscience, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.7

Sabrina Martucci Johnson changed role as Chief Executive Officer and President at Dare Bioscience, Inc..

Action: will serve as principal financial officer
Role: Chief Executive Officer and President

Exact text from the filing

Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer

View on SEC.gov

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-003984

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.